At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Glucagon-Like Peptide 1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Effects of GLP-1 on Renal Hemodynamics: Simultaneous Perfusion and Oxygenation Measurements in Cortex and Medulla Using Magnetic Resonance Imaging
In Brief
A clinical study evaluating Glucagon-Like Peptide 1 and saline 0.9% for The GLP-1-mediated Gut-kidney Axis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study investigates the hypothesis, that GLP-1's suppression of ANG II and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThe GLP-1-mediated Gut-kidney Axis
CountriesDenmark
CollaboratorsUniversity of Southern Denmark
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
Primary CompletionMar 2020
First PostedApr 2020
TodayJul 2026
First PostedApr 7, 2020
Enrollment StartApr 1, 2019
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.2 years ago
Interventions
Glucagon-Like Peptide 1drug
Intravenous infusion (1.5 pmol/kg/min) for 60 min.
saline 0.9%drug
Intravenous infusion for 60 min.